Harvard Bioscience, Inc. (HBIO) Income Statement Analysis

See more : Asahi Intecc Co., Ltd. (7747.T) Income Statement Analysis – Financial Results

Complete financial analysis of Harvard Bioscience, Inc. (HBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Harvard Bioscience, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.

You may be interested

oOh!media Limited (OML.AX) Income Statement Analysis – Financial Results
Tinkerine Studios Ltd. (TKSTF) Income Statement Analysis – Financial Results
Shanghai Challenge Textile Co.,Ltd. (002486.SZ) Income Statement Analysis – Financial Results
Handelsinvest – Defensiv 10 (HAID10A.CO) Income Statement Analysis – Financial Results
COOCON Corporation (294570.KQ) Income Statement Analysis – Financial Results

Harvard Bioscience, Inc. (HBIO)

Industry: Medical - Instruments & Supplies

Sector: Healthcare

Website: https://www.harvardbioscience.com

About Harvard Bioscience, Inc.

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.

Metric	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003	2002	2001	2000	1999	1998
Revenue	112.25M	113.34M	118.90M	102.10M	116.18M	120.77M	101.88M	104.52M	108.66M	108.66M	105.17M	111.17M	108.86M	108.18M	85.77M	88.05M	83.41M	76.18M	67.43M	92.60M	87.14M	57.38M	40.87M	30.57M	26.18M	12.15M
Cost of Revenue	46.18M	52.52M	51.25M	44.06M	51.85M	57.59M	54.29M	56.11M	59.94M	59.32M	57.48M	58.75M	58.60M	56.40M	44.09M	45.89M	43.16M	38.09M	34.16M	46.52M	43.73M	28.82M	20.64M	15.10M	12.72M	5.35M
Gross Profit	66.07M	60.82M	67.65M	58.04M	64.32M	63.18M	47.60M	48.42M	48.72M	49.34M	47.70M	52.42M	50.26M	51.78M	41.68M	42.16M	40.25M	38.09M	33.28M	46.07M	43.41M	28.56M	20.23M	15.47M	13.46M	6.80M
Gross Profit Ratio	58.86%	53.66%	56.90%	56.85%	55.37%	52.31%	46.72%	46.32%	44.84%	45.41%	45.35%	47.15%	46.17%	47.86%	48.60%	47.88%	48.25%	50.00%	49.35%	49.76%	49.82%	49.77%	49.50%	50.61%	51.40%	55.97%
Research & Development	11.76M	12.33M	10.80M	8.69M	10.72M	10.99M	5.65M	5.39M	6.42M	4.88M	4.15M	7.32M	5.43M	4.71M	4.40M	4.05M	3.71M	3.15M	2.95M	7.19M	6.26M	4.15M	3.18M	1.53M	1.19M	325.00K
General & Administrative	22.78M	24.49M	24.31M	23.51M	22.76M	21.38M	18.58M	20.95M	19.83M	16.83M	19.94M	19.70M	18.06M	17.64M	15.11M	26.10M	25.18M	24.55M	20.74M	31.06M	26.78M	18.89M	14.52M	0.00	0.00	0.00
Selling & Marketing	24.11M	25.04M	24.64M	19.92M	23.26M	24.44M	21.04M	20.49M	20.58M	18.23M	17.33M	19.17M	17.47M	16.35M	11.76M	10.97M	10.35M	9.50M	8.11M	16.82M	15.38B	8.44B	4.84B	0.00	0.00	0.00
SG&A	46.89M	49.53M	48.95M	43.43M	46.02M	45.83M	39.61M	41.44M	40.41M	35.05M	37.27M	38.87M	35.54M	33.99M	26.87M	26.10M	25.18M	24.55M	20.74M	31.06M	26.78M	18.89M	14.52M	22.78M	9.88M	4.04M
Other Expenses	5.60M	6.12M	5.84M	5.71M	5.75M	-4.28M	-740.00K	-179.00K	-1.26M	-1.14M	-51.00K	-287.00K	2.75M	2.36M	1.84M	1.97M	1.82M	1.70M	1.67M	3.45M	2.70M	1.54M	1.74M	1.49M	1.26M	27.00K
Operating Expenses	64.50M	67.99M	65.59M	57.82M	62.49M	62.20M	47.70M	49.55M	49.65M	42.51M	44.01M	48.94M	43.72M	41.06M	33.11M	32.12M	30.71M	29.40M	25.35M	41.69M	35.75M	24.58M	19.44M	25.80M	12.32M	4.39M
Cost & Expenses	110.36M	120.50M	116.84M	101.88M	114.34M	119.79M	101.98M	105.66M	109.59M	101.83M	101.48M	107.70M	102.32M	97.46M	77.20M	78.01M	73.87M	67.49M	59.51M	88.22M	79.48M	53.40M	40.08M	40.90M	25.04M	9.74M
Interest Income	0.00	2.55M	1.54M	4.83M	5.41M	0.00	0.00	3.00K	8.00K	74.00K	43.00K	46.00K	65.00K	65.00K	29.00K	372.00K	317.00K	216.00K	234.00K	136.00K	175.99K	445.67K	1.36M	159.85K	0.00	0.00
Interest Expense	3.59M	2.25M	1.54M	4.83M	5.41M	5.37M	713.00K	642.00K	854.00K	990.00K	955.00K	584.00K	752.00K	677.00K	277.00K	389.00K	365.00K	429.00K	917.00K	794.00K	327.23K	104.18K	6.87K	916.21K	0.00	0.00
Depreciation & Amortization	7.00M	7.58M	7.62M	7.63M	7.73M	7.84M	2.91M	4.27M	2.82M	2.58M	3.99M	4.21M	2.75M	2.36M	1.84M	3.10M	3.47M	3.34M	5.04M	6.35M	5.29M	3.01M	2.97M	1.49M	1.26M	27.00K
EBITDA	8.03M	944.00K	11.31M	5.49M	7.50M	5.36M	-101.00K	1.80M	1.73M	9.29M	7.67M	11.68M	11.95M	13.80M	13.14M	11.14M	9.53M	8.69M	12.96M	14.73M	12.95M	6.99M	3.76M	-8.84M	2.39M	2.44M
EBITDA Ratio	7.16%	-0.92%	6.09%	5.02%	6.21%	1.73%	1.57%	1.35%	0.59%	7.69%	7.29%	6.69%	8.59%	12.15%	12.18%	17.61%	15.50%	15.89%	19.37%	11.39%	15.17%	15.61%	22.79%	93.51%	122.81%	20.07%
Operating Income	1.89M	-7.17M	1.40M	-585.00K	1.47M	984.00K	-101.00K	-3.00M	-1.71M	6.62M	1.54M	3.17M	6.08M	10.22M	8.06M	8.48M	9.53M	8.69M	7.92M	4.38M	7.67M	1.64M	-4.66M	-10.33M	1.13M	2.41M
Operating Income Ratio	1.69%	-6.32%	1.18%	-0.57%	1.27%	0.81%	-0.10%	-2.87%	-1.58%	6.09%	1.46%	2.85%	5.58%	9.45%	9.39%	9.63%	11.43%	11.41%	11.75%	4.73%	8.80%	2.86%	-11.40%	-33.77%	4.33%	19.85%
Total Other Income/Expenses	-4.45M	-2.25M	-2.21M	-7.51M	-5.88M	-8.96M	-1.99M	-81.00K	-1.90M	-2.20M	-1.10M	-5.60M	-1.54M	-655.00K	1.76M	-829.00K	35.00K	-294.00K	-784.00K	3.25M	-428.00K	707.00K	1.24M	-38.18M	-30.42M	-1.56M
Income Before Tax	-2.56M	-9.18M	-140.00K	-7.29M	-5.50M	-8.52M	-2.09M	-3.08M	-3.61M	4.42M	435.00K	2.23M	4.54M	9.56M	9.81M	7.65M	9.57M	8.40M	7.14M	3.80M	7.24M	2.35M	-3.42M	-48.51M	-29.28M	854.00K
Income Before Tax Ratio	-2.28%	-8.10%	-0.12%	-7.14%	-4.74%	-7.05%	-2.05%	-2.94%	-3.32%	4.06%	0.41%	2.00%	4.17%	8.84%	11.44%	8.69%	11.47%	11.02%	10.59%	4.10%	8.30%	4.09%	-8.36%	-158.66%	-111.86%	7.03%
Income Tax Expense	859.00K	337.00K	148.00K	518.00K	-815.00K	-3.68M	-1.22M	1.23M	15.43M	2.06M	-288.00K	696.00K	730.00K	-9.45M	2.67M	2.24M	1.97M	1.78M	899.00K	1.47M	2.98M	1.61M	1.79M	1.36M	137.48K	783.00K
Net Income	-3.42M	-9.52M	-288.00K	-7.81M	-4.69M	-3.46M	-865.00K	-4.31M	-19.04M	2.36M	-1.83M	2.37M	3.81M	19.02M	7.23M	1.67M	-1.35M	-2.34M	-31.88M	2.33M	4.26M	737.33K	-5.21M	-49.87M	-29.42M	71.00K
Net Income Ratio	-3.04%	-8.40%	-0.24%	-7.65%	-4.03%	-2.87%	-0.85%	-4.12%	-17.52%	2.17%	-1.74%	2.13%	3.50%	17.58%	8.43%	1.90%	-1.62%	-3.07%	-47.27%	2.52%	4.89%	1.28%	-12.74%	-163.11%	-112.38%	0.58%
EPS	-0.08	-0.23	-0.01	-0.20	-0.12	-0.10	-0.03	-0.13	-0.57	0.07	-0.06	0.09	0.13	0.66	0.24	0.05	-0.04	-0.08	-1.05	0.08	0.14	0.03	-0.20	-6.23	-5.25	-0.01
EPS Diluted	-0.08	-0.23	-0.01	-0.20	-0.12	-0.10	-0.02	-0.13	-0.57	0.07	-0.06	0.08	0.13	0.65	0.24	0.05	-0.04	-0.08	-1.04	0.07	0.14	0.03	-0.20	-6.23	-5.25	-0.01
Weighted Avg Shares Out	42.42M	41.41M	40.34M	38.64M	37.81M	35.83M	33.60M	34.21M	33.59M	32.17M	30.38M	28.80M	28.45M	28.97M	29.65M	30.88M	30.65M	30.52M	30.44M	30.27M	29.92M	27.09M	25.78M	8.01M	5.60M	5.60M
Weighted Avg Shares Out (Dil)	42.42M	41.41M	40.34M	38.64M	37.81M	36.45M	34.75M	34.21M	33.59M	33.24M	31.91M	29.79M	29.82M	29.41M	29.95M	31.35M	31.41M	31.15M	30.78M	31.10M	30.71M	27.60M	25.78M	8.01M	5.60M	5.60M

The 10 best global universities of 2021, according to U.S. News

October 20, 2020cnbc.com

For the ranking, U.S. News analyzed the data of nearly 1,500 schools from 86 countries across 13 different variables.

Lagarde Schedules Her Priorities For The ECB's New Monetary Policy Framework

October 19, 2020seekingalpha.com

Conflating the COVID-19 pandemic with Climate Change may be the best way for Christine Lagarde to schedule her MMT priorities for the ECB’s new monetary policy framework.